INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2014

Extended-release niacin with laropiprant did not reduce major vascular events but increased serious adverse events in high-risk patients on statins.

A randomized trial assigned 25,673 adults with vascular disease receiving background statin therapy to 2 g extended-release niacin plus 40 mg laropiprant daily or matching placebo for a median of 3.9 years. Niacin-laropiprant lowered LDL cholesterol by 10 mg/dL and increased HDL cholesterol by 6 mg/dL compared to placebo, but had no significant effect on major vascular events (13.2% vs. 13.7%; rate ratio 0.96; 95% CI, 0.90 to 1.03; P=0.29). It was associated with significant absolute excesses in serious diabetes disturbances (3.7 percentage points), diabetes diagnoses (1.3 percentage points), and serious gastrointestinal, musculoskeletal, skin, infection, and bleeding adverse events.

Study type
Randomized controlled trial
Who was studied
25,673 adults with vascular disease on background statin therapy
What was measured
First major vascular event and adverse events

THE PAPER

Effects of extended-release niacin with laropiprant in high-risk patients.

HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. N Engl J Med, 2014.

PubMed 25014686 ↗DOI 10.1056/nejmoa1300955 ↗

Heart & arteriesDiabetes & blood sugar

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.